Clinical Trial Detail

NCT ID NCT03063203
Title Single Agent Decitabine in TP53 Mutated Relapsed/Refractory Acute Myeloid Leukemia
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Washington University School of Medicine
Indications

acute myeloid leukemia

Therapies

Decitabine

Age Groups: adult senior

No variant requirements are available.